Establishing and operating a ‘virtual ward’ system to provide care for patients with COVID-19 at home: experience from The Gambia

Ogbenbrume Wariri,1 Uduak Okomo,1 Carla Cerami,2 Emmanuel Okoh,3 Francis Oko,1 Hawanatu Jah,3 Kalifa Bojang,3 Bubacarr Susso,4 Yekini Olatunji,3 Esin Nkereuwem,1 Fatai Momodou Akemokwe,4 Modou Jobe,2 Orighomisan Freda Agboghoroma,4 Bunja Kebbeh,4 Ghata Sowe,1 Thomas Gilleh,5 Naffie Jobe,6 Effua Usuf,3 Ed Clarke,1 Helen Brotherton,3,7 Karen Forrest4

ABSTRACT
Health systems in sub-Saharan Africa have remained overstretched from dealing with endemic diseases, which limit their capacity to absorb additional stress from new and emerging infectious diseases. Against this backdrop, the rapidly evolving COVID-19 pandemic presented an additional challenge of insufficient hospital beds and human resource for health needed to deliver hospital-based COVID-19 care. Emerging evidence from high-income countries suggests that a ‘virtual ward’ (VW) system can provide adequate home-based care for selected patients with COVID-19, thereby reducing the need for admissions and mitigate additional stress on hospital beds. We established a VW at the Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, a biomedical research institution located in The Gambia, a low-income west African country, to care for members of staff and their families infected with COVID-19. In this practice paper, we share our experience focusing on the key components of the system, how it was set up and successfully operated to support patients with COVID-19 in non-hospital settings.

INTRODUCTION
From the time it was first confirmed in December 2019, COVID-19 has spread to six continents, with more than 119 million cases and 2.6 million deaths registered as of mid-March 2021. The first case of COVID-19 in Africa was confirmed on 14 February 2020 in Egypt and by mid-April 2020, there were already 19,895 cases reported across 52 of the 54 countries in the continent. As with other pandemics, the COVID-19 pandemic has had direct and indirect effects on populations in every country. While the reported effects on morbidity and mortality appear to be less intense in some countries, the staggering levels of morbidity and mortality in other countries together with the increased need for facility care have severely stretched, in some cases overwhelmed, their health systems—irrespective of the per capita gross national income.

Health systems in Africa were already stretched thin from dealing with endemic infectious disease, non-communicable diseases, maternal and child health issues...
prior to the onset of the COVID-19 pandemic. In this context, their capacity to absorb additional stress from a widespread outbreak was limited. Early mathematical models had suggested that Africa could be the most vulnerable continent. It was also anticipated that higher incidence of severe forms of COVID-19 could occur in Africa due to the high prevalence of conditions that impair the immune system: tuberculosis, HIV/AIDS, malaria, anaemia and underlying malnutrition. Furthermore, there was the additional challenge of insufficient critical care beds and human resources for health (HRH) needed to support severe forms of COVID-19. This led to shifts of HRH from other areas to support COVID-19 care, thus creating shortages of clinical staff to support routine health services. The shortages of HRH needed to sustain routine services have dire consequences such as the reduction in maternal, newborn and child health services, which might halt progress towards global health targets.

As the pandemic progressed, there was a reorganisation of the health service delivery systems to mitigate the potential impact of the crisis. While there is a global consensus regarding the general principles of prevention and case management, many countries have also implemented context specific strategies that suited their local realities, such as the adoption of digital communication tools to deliver safe virtual care for COVID-19 patients and to coordinate the response to the pandemic. Digital health or telemedicine holds enormous promise as it reduces the risk of exposure to COVID-19 by health workers, takes the pressure off the healthcare system and keeps clinical staff and patients connected even when they must be physically apart.

Remote home monitoring of patients also known as the ‘virtual ward’ (VW) system involves the use of information and communications technology platforms by clinical teams to provide care for patients. VW systems have been used to provide care for patients with other medical conditions prior to the onset of COVID-19, with varied implementation models and patient outcomes. Since the onset of the COVID-19 pandemic, reported VW systems have used digital platforms, and/or paper-based diaries with accompanying telephone calls to care for patients. The majority of COVID-19 VW systems reported so far have been implemented in the USA and UK and have been shown to reduce the need for admissions and mitigate pressure on hospital beds. However, the focus of existing literature on COVID-19 VW systems has been the clinical outcomes associated with the system, with less on the experience and processes involved in setting up and operationalising such systems. To the best of our knowledge, there is no literature describing the use of the VW system to support patients with COVID-19 in sub-Saharan African countries. In this practice paper, we hope to bridge this important gap by sharing our experience of setting up and operating a VW system to provide care for patients with COVID-19 in a biomedical research institution in The Gambia, West Africa.

Figure 1 Weekly Epi-curve of confirmed COVID-19 cases among MRCG at LSHTM staff and the national (The Gambia) cases from 4 July 2020 to 29 October 2020 (first wave of COVID-19 in The Gambia). Sources: MRCG at LSHTM cases (internal database) and total cases in The Gambia (www.moh.gov.gm). LSHTM, London School of Hygiene and Tropical Medicine; MRCG, Medical Research Council Unit The Gambia.

Setting and Context

The Gambia is a low-income west African country, with a per capita health expenditure in 2017 of US$23, and has a population of 2.4 million people. There are estimated 11 hospital beds per 10 000 of the population and one physician per 10 000 of the population as of 2015.

The first case of COVID-19 in The Gambia was confirmed on 17 March 2020 as an imported case in an adult female. By the end of June 2020, just over 3 months since the index case was confirmed, only 48 additional cases were detected in the country. However, between July 2020 and September 2020, the number of cases rapidly increased and peaked, with 3579 COVID-19 cases (ie, 15 cases per 10 000 population) confirmed by the end of September 2020 (figure 1).

Until late August 2020, the national case management policy specified that all confirmed COVID-19 cases be isolated in government designated treatment centres where they would be managed until they tested negative twice before discharge. Individuals who were considered to have been significant contacts of positive cases were also quarantined in designated hotels at no personal cost. As the number of confirmed cases peaked, there was a significant strain on hospital beds at the designated national treatment centres. This situation was due, in part, to the national criteria that required in-facility care for all confirmed cases and two negative SARS-CoV-2 PCR test before their discharge from in-hospital care. There was, however, a national change to the WHO symptomatic criteria for releasing patients with COVID-19 from isolation in late August 2020.

The Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine (MRCG at LSHTM) is a biomedical research institution operational in The Gambia for more than 70 years and has over 1300 employees. The MRCG at LSHTM has a 42-bed Clinical Services Department (CSD), which provides outpatient and inpatient clinical care for its
staff and their relatives, study participants and the local population. Apart from these responsibilities, the CSD is one of only two hospital facilities in The Gambia that supports inpatient management of patients with severe COVID-19. As part of a wider COVID-19 preparedness, at the beginning of the pandemic, the MRCG at LSHTM made several changes to its clinical systems in the CSD such as setting up an additional 30 beds for patients with COVID-19. A comprehensive reorganisation of inpatient and outpatient services, development of operational and clinical guidelines with training, and establishment of a consultant-led multidisciplinary team to provide dedicated COVID-19 care was also done.

Four months after the index case was confirmed in The Gambia, the first case of COVID-19 among an MRCG at LSHTM staff was identified on 18 July 2020 and cases subsequently increased rapidly as illustrated in figure 1. After the confirmation of the first staff case, the MRCG at LSHTM constituted a Staff COVID-19 Risk Coordination (SCRIC) team on 23 July 2020 to coordinate responses and actions and ensure the highest possible standards for staff. The SCRIC team commenced operation of the VW system when it became apparent that the hospitalisation of all asymptomatic and symptomatic COVID-19 cases, as was the procedure at the time, was not sustainable because it added intense pressure on the limited CSD beds and frontline HRH. See figure 2 showing the timeline of the key events leading up to the establishment and operationalisation of the VW system.

THE REMIT OF THE ‘VIRTUAL WARD’ SYSTEM
The objectives of the VW system is to provide home-based support for a subset of COVID-19 cases meeting certain criteria, ensure they are closely monitored and escalate if they deteriorate, thereby avoiding unnecessary hospital admission for COVID-19. The eligibility criterion for our VW system is a primary diagnosis of COVID-19 in patients who have not already been admitted to the hospital. Such patients must have asymptomatic or mild/moderate symptoms of the disease and be staff members (or their immediate relatives) who, based on their clinical presentation and assessment of risk factors by a clinician, are at low risk of progressive disease. Because our VW system requires that patients be primarily isolated at home, another eligibility requirement is that the home and social setting must be ideal for home isolation.

The key components of our VW system are shown in figure 3. To access care through the system, staff and their immediate relatives with symptoms of COVID-19 or those who have had significant contact with a confirmed case are advised to call the staff COVID-19 hotline (ie, the internal hotline which operates 24 hours a day, 7 days a week) about their symptoms and for general enquiries. The internal COVID-19 hotline is operated by a team of clinicians who use a set of questions and a checklist adapted from the WHO guidelines to triage patients and determine who would require a diagnostic test. A SARS-CoV-2 PCR test is then organised for those who meet the requirements and results are communicated to them within the next 12–24 hours. The subsequent pathway of care (ie, virtual care or hospital admission) is determined based on the individual’s test result and severity of symptoms.

All patients confirmed COVID-19-positive and who qualify for virtual care are assigned an SCRIC physician and provided with a digital thermometer to monitor daily axillary temperature. Pulse oximeter are provided on a case-by-case basis to aid the monitoring of oxygen saturation. Pulse oximeters are given to patients who have a significant background medical condition, those who are above 55 years, or those considered by their assigned physician to have a high risk of respiratory deterioration. The assigned SCRIC physician adopts a virtual monitoring...
plan based on standard COVID-19 care guidelines and provides additional support as required during scheduled follow-up teleconsultation. The temperatures and oxygen saturation readings taken by the patients are fed back to physician during each ‘VW rounds’, and patients are also instructed to immediately call the SCRIC physician if their readings were above or below certain predetermined thresholds. The VW system also provides a safe accommodation on site (ie, within the MRCG at LSHTM facilities) for staff isolation where home circumstances were not suitable for home isolation. If any patient in the VW developed severe symptoms, they were reviewed and transferred to the MRCG at LSHTM CSD for inpatient hospital care.

From 24 August 2020 when the VW became operational to 31 April 2021, 427 patients who are COVID-19 positive (MRCG at LSHTM staff and their relatives) have been admitted, followed-up and discharged through the VW system. Of these, 75% (321/427) were staff, while 25% (106/427) were immediate relatives of staff (table 1). So far, about 2% of the 427 cases managed through the system developed severe disease warranting in-hospital care and were transferred to the MRCG at LSHTM CSD. So far, all the cases with severe disease have been successfully managed in the CSD, transferred back into the VW and discharged from follow-up in the VW with no mortality recorded.

THE COMPOSITION AND FUNCTION OF THE TEAM

To ensure the effective operation of the VW system, and provide quality COVID-19 follow-up and care, we constituted a multidisciplinary team made up of a cross-section of clinical staff (14 physicians and 10 nurses who are duly registered as practitioners in The Gambia), four project management and administrative staff, and a dedicated ambulance driver. Furthermore, we leveraged existing structures within the MRCG at LSHTM, working closely with our CSD, health and safety department, and clinical and research laboratories, which also continue to support the national SARS-CoV-2 PCR testing throughout the country.

The physicians on the team are responsible for communicating with known contacts of cases to confirm exposure, organise for such contacts to undergo a diagnostic test 3–5 days after the last known exposure, communicate positive results and provide clinical assessment and care during the VW round. The nursing staff collect the diagnostic nasopharyngeal and oropharyngeal swabs on an outpatient basis at the MRCG at LSHTM and transport samples to the clinical laboratory for SARS-CoV-2 PCR testing. The project management and administrative staff handle data entry, non-clinical communication and ensure smooth day-to-day running of the system. The ambulance drivers are on hand to provide safe transport...
for patients who may require transfer from their homes to the CSD for testing, or clinical evaluation if their clinical condition necessitates a transfer at any time during their follow-up.

At the beginning of the pandemic, physicians who found themselves away from The Gambia and unable to return due to travel restrictions at the time were drafted into the team if they wished to support the VW system. This was possible because of the virtual nature of our system, which enabled our physicians to provide care for patients with COVID-19 remotely. We have also been able to leverage the services of other physicians among our staff who are unable to provide face-to-face clinical services or continue with research activities because they have been assessed to be at risk for severe COVID-19 as a result of their background medical condition that warrants their shielding. Through this approach, we have been able to operate a diverse team of physicians with varied experience and located across three continents (Africa, Europe and North America). Thus, we continue to use critical clinical manpower that would have ordinarily not been available and complement the clinical care provided by the team on the ground in The Gambia as the pandemic continues.

CLINICAL OVERSIGHT

An assigned physician member of the team (ie, an individual who is medically qualified to provide clinical patient care and registered in The Gambia) has primary clinical oversight for each patient being followed-up through the VW system. To ensure consistency of the process and continuity of care provided, each patient had one SCRIC physician assigned to them from admission process and continuity of care provided, each patient had our staff who are unable to provide face-to-face clinical services or continue with research activities because they have been assessed to be at risk for severe COVID-19 as a result of their background medical condition that warrants their shielding. Through this approach, we have been able to operate a diverse team of physicians with varied experience and located across three continents (Africa, Europe and North America). Thus, we continue to use critical clinical manpower that would have ordinarily not been available and complement the clinical care provided by the team on the ground in The Gambia as the pandemic continues.

GUIDELINES

There is evidence supporting the potential positive impact of clinical guidelines and standard operating procedures (SOPs), on improving the quality and the consistency of care provided by teams of clinicians to patients. The SCRIC team developed SOPs and guidelines, which provides clear and stepwise processes and govern all the aspects of care that the team provides (see Box 1). These guideline documents clearly specify team members’ responsibilities and provide a detailed and stepwise description of each process. Example of issues covered by these SOPs and guidelines include how staff can access the system, how and when swabbing for SARS-CoV-2 swabbing is arranged, what clinical information to be collected before and after a test to aid informed decisions, who communicates test results and how this should be done. There are also guidelines on how the initial triage of patient is to be is conducted (online supplemental appendix 1), what criteria determines if a patient would require hospital care rather than a virtual follow-up, how and when the subsequent follow-up should be conducted and the process of terminating virtual follow-up.

At the outset, we prioritised the drafting of these guidelines and the training of team members to ensure they were comfortable with them before their implementation. All guidelines are drafted and are continuously updated in line with the best available evidence at the time, current WHO COVID-19 guidelines and recommendations, and put into the context of the prevailing national guidelines being implemented in The Gambia.
TELECONSULTATION AND COMMUNICATION SYSTEMS

To conduct virtual consultation and follow-up, we relied on mobile telephones and messaging applications such as WhatsApp. Most members of staff at the MRCG at LSHTM are connected by a closed user group on their mobile phones through a local telecommunication service provider; hence, the default mode of teleconsultation and communication between team members was the use of mobile telephones. However, ‘VW rounds’ were also conducted through WhatsApp by our team of physicians who were outside The Gambia and in scenarios where video consultation was explicitly required by the team on the ground. We resorted to the use of WhatsApp as a telecommunication tool in these scenarios because it is an inexpensive solution suitable for our physicians abroad who faced prohibitive cost of international phone. Additionally, WhatsApp video-conferencing offered a platform and the ability to conduct a more complete clinical assessment.31 Although internet penetration (ie, individuals using the internet) was about 20% of the general Gambian population as of January 2020,32 the much higher internet penetration for staff members of the MRCG at LSHTM made the use of the video-conferencing option more feasible.

DATA CAPTURE AND MANAGEMENT

To ensure a seamless virtual management of patients with COVID-19 by our team working remotely together, we use the Research Electronic Data Capture (REDCap) database to capture, share and securely store patient data. REDCap is a web-based application that provides a highly secured environment, suitable for storage of sensitive patient information and which is intuitive to use for research and clinical teams.33 The database was designed by the MRCG at LSHTM data management team, in collaboration with the SCRIC team and all the clinical team members have remote access to the database. Patient data captured in the database include basic biodata, history of contact/exposure to confirmed cases, symptomatology, background medical conditions and results of all SARS-CoV-2 tests conducted. We also capture all clinical notes and decisions made throughout the virtual follow-up process.

LIMITATIONS AND CHALLENGES OF THE VIRTUAL WARD SYSTEM

The implementation and sustainability of our VW system has been subject to two main challenges. The first has been maintaining optimal staffing to operate the VW system. At the time the system was implemented at the peak of the first wave of the pandemic in The Gambia in mid-2020, most non-essential activities in our unit had been halted thereby enabling secondment of some of the clinical and non-clinical staff from their primary research, and administrative roles to support the system. With the resumption of normal duties after the first wave, many staff have returned to their routine duties. Although they still continue to provide some support, the demands of their routine workloads limits how much support they can reasonably provide. The second challenge has been securing continued funding to sustain the additional staffing, consumables and logistics requirement for the system. Financial resources are finite, even more so during a pandemic, which continue to stretch to the limits existing budget lines. An economic analyses of the VW will be useful to highlight the utility and potential cost savings, or the additional cost of operating the VW system.

POTENTIAL IMPLEMENTATION AND OPERATIONAL CHALLENGES FOR OTHER SETTINGS

For the successful establishment and operation of the VW in other resource-limited settings, there are potential implementation bottlenecks that must be considered. First, internet penetration in most resource-limited setting is sometimes patchy and could impede the success of the VW system, especially for video-conferencing and electronic data capture. How poor internet penetration and low quality bandwidth hampers the feasibility and utility of remote healthcare delivery models in sub-Saharan is well documented.15 We overcame this operational challenge because internet penetration is generally high among the cohort of people the system supported and the MRCG at LSHTM has an excellent network infrastructure, the use of the paper-based diaries and phone call VW models could bridge this gap even as the pandemic evolve across Africa.

Second, although this VW system has worked well so far in our setting, as mentioned above, it is not without cost to the MRCG at LSHTM. While many VW systems are embedded within existing healthcare budgets, ensuring their long-term sustainability requires additional funding. Thus, detailed budgeting for additional cost such as data capture systems, telephone communication, internet charges, consumables (thermometers, pulse oximeters, etc) and logistics must be considered before the implementation of the VW system. This is even more important especially in sub-Saharan Africa, where such cost is often not equitably budget for at primary-level and secondary-level public healthcare facilities.34

Third, the VW requires HRH who can dedicate time to run the system. Similar to the model we operated, during the COVID-19 pandemic, many VW systems in high-income countries reallocated HRH from non-emergency clinical setting to support the implementation of the model.35 36 Nevertheless, HRH in many low-income and middle-income countries is limited and they are already overstretched from supporting in-hospital care for COVID-19 and other diseases, thus, potentially limiting their availability to support a VW system. The feasibility of implementing VWs in sub-Saharan Africa requires that
With COVID-19 in non-hospital settings. We demonstrate that a VW system for the care of patients with COVID-19 in non-hospital settings is feasible in a low-income country in west Africa. We believe that other low-income or resource-constrained settings can adopt and contextualize the processes described here to safely support patients with COVID-19 in non-hospital settings.

CONCLUSION

We have described the processes involved in setting up and operating a successful VW system at the MRCG at LSHTM to manage staff and their family members who developed asymptomatic, mild or moderate COVID-19. We demonstrate that a VW system for the care of patients with COVID-19 in non-hospital settings is feasible in a low-income country in west Africa. We believe that other low-income or resource-constrained settings can adopt and contextualize the processes described here to safely support patients with COVID-19 in non-hospital settings.

Author affiliations

1Vaccines and Immunity Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia
2Nutrition Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia
3Disease Control and Elimination, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
4Clinical Services Department, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
5Data Management and Archives, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
6Directorate, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
7Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

Twitter Ognehbrune Wariri @dwariri

Contributors All named authors made substantial contributions to establishing/operating the virtual ward (VW), or the conceptualisation of the practice paper, or the drafting of the manuscript, and critically reviewing the manuscript. OW led the implementation and coordination of the VW during the first wave of COVID-19 in the Gambia and conceptualised the idea for this practice paper. All authors approved the final version and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding The work reported here was supported by funding from the European Commission (reference number: FED/2020/417-470) through the ‘Support and strengthen the public health and socioeconomic systems to reduce the impact of the Covid-19 pandemic in The Gambia’. HB was supported by Wellcome Trust grants [200116/Z/15/Z] as a clinical COVID-19 secondment. The funder of the Covid-19 pandemic in The Gambia. HB was supported by Wellcome Trust grant [200116/Z/15/Z] as a clinical COVID-19 secondment. The funder of the Covid-19 pandemic in The Gambia.

Disclaimer The views expressed in this practice paper are those of the authors and do not necessarily reflect those of their parent organisation: The Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement There are no data in this work.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iD Ognehbrune Wariri http://orcid.org/0000-0002-7432-8995

REFERENCES

2 WHO Regional Office for Africa. COVID-19 cases top 10 000 in Africa. 2020. Available: https://www.afro.who.int/news/covid-19-cases-top-10-000-africa#:--text=Reaching%2020%20continent%20through%20travellers,countries%20have%20reported%20cases


